Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AB SCIEX Announces Company’s First In Vitro Diagnostic Device

Published: Wednesday, February 13, 2013
Last Updated: Wednesday, February 13, 2013
Bookmark and Share
AB SCIEX 3200MD series delivers the power of mass spectrometry for adoption in hospitals and clinical labs.

AB SCIEX has introduced the AB SCIEX API 3200MD™ and 3200MD QTRAP® LC/MS/MS systems, two devices that can be used to analyze trace levels of multiple compounds in human samples for diagnostic purposes.

Mass spectrometry is an analytical technology that has the potential to improve the quality of results for use in clinical diagnostics, while reducing costs compared to other technologies.

“Clinical diagnostics is the new frontier for mass spectrometry,” said Rainer Blair, President of AB SCIEX. “The introduction of the 3200MD series is a major milestone for AB SCIEX itself in response to the demand in clinical settings for mass spectrometers as medical devices that meet regulatory requirements.”

The 3200MD series is the first of a family of in vitro diagnostic devices that AB SCIEX plans to roll out around the world in the future.

The intended use of these devices is to identify inorganic or organic compounds in human specimens for clinical use.

The introduction of this new family of in vitro diagnostic devices follows up AB SCIEX’s announcement in 2012 of obtaining ISO 13485:2003 certification.

ISO 13485:2003 is an ISO standard that represents the requirements for a comprehensive quality management system for the design and manufacture of medical devices.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Collaboration to Develop Cannabis Testing Standards
SCIEX workflow solution enables cannabis labs to ensure product safety with robust, cost-effective analytical methods to facilitate routine testing.
Tuesday, September 13, 2016
SCIEX Works with the Francis Crick Institute and the University of Cambridge
New proteomic study to develop advanced resource for precision medicine research by using Microflow SWATH® Acquisition for HT industrialized proteomics.
Wednesday, June 29, 2016
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Friday, June 17, 2016
SCIEX, QPS Holdings Collaborate
Agreement aims to advance the hybrid LBA-LCMS workflow for biologics quantification.
Wednesday, April 06, 2016
SCIEX, Children's Medical Research Institute Collaborate
SCIEX industrialized proteomics solutions, using SWATH® Acquisition-based workflows and powered by the OneOmics™ Project, will enable large scale proteome studies to advance cancer research.
Thursday, February 11, 2016
SCIEX, A*STAR’s BTI Launch Collaboration
Agreement aims to boost innovation of protein drugs that target new diseases and are safer for patients.
Wednesday, January 27, 2016
SCIEX, Pressure BioSciences Partner
SCIEX and Pressure BioSciences to offer complete solution for next-generation proteomics, to increase the reproducibility and depth of proteomic analysis.
Wednesday, January 13, 2016
SCIEX, University of Manchester Partner
SWATH® Acquisition-based next-generation proteomics technology promises to make industrial proteomics a reality.
Thursday, October 29, 2015
SCIEX Partners with the Paulovich Lab at Fred Hutchinson Cancer Research Center
Collaboration targets research reproducibility crisis with highly validated multiplex quantitation assays.
Wednesday, September 23, 2015
SCIEX and New Objective Announce Partnership
New nanospray sources to offer maximum sensitivity and robustness for NanoLC-MS.
Tuesday, June 02, 2015
SCIEX and New Objective Partner
Partnership will provide advanced nanospray ionization technologies for next-generation proteomics.
Tuesday, May 26, 2015
SCIEX and Hepregen Announce Co-Marketing Agreement
Alliance establishes SCIEX and Hepregen as a one-stop solution provider for drug metabolism investigators.
Friday, May 22, 2015
Sciex, Hepregen Team up on Metabolite Identification Offering
This recently announced collaboration aims to provide practical solutions for drug metabolism researchers.
Thursday, May 21, 2015
Dr. Gyula Vigh wins Arnold O. Beckman Award
SCIEX sponsored award recognizes outstanding contributions to the field of electrodriven separation techniques.
Thursday, May 07, 2015
SCIEX and Mass Consortium Corporation Announce Exclusive Reseller Agreement
SCIEX to provide customers with XCMSplus software solution for simplified and accelerated metabolomics workflows.
Tuesday, March 31, 2015
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
New Imaging Technique in Alzheimer’s Disease
Study confirms new imaging technique corresponds a higher degree of actual brain changes.
Identified Compound Stops Cells Making Ribosomes
From study in yeast, researchers have identifed a compound that interferes with the assembly of ribosomes.
Anti-Inflammatory Drugs Could Strengthen Airway Immunity
Mold toxins can weaken the airways' clearing mechanisms and immunity, but PKC inhibitors showed promise as a treatment.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!